Inhibition of LSD1 was proposed as promising and attractive therapies for treating osteoporosis. Here, we synthesized a series of novel TCP-(MP)-Caffeic acid analogs as potential LSD1 inhibitors to assess their inhibitory effects on osteoclastogenesis by using TRAP-staining assay and try to explore the preliminary SAR. Among them, TCP-MP-CA () demonstrated osteoclastic bone loss both and , showing
L
SD1 的抑制被认为是治疗骨质疏松症的有前途且有吸引力的疗法。在这里,我们合成了一系列新型
TCP-(MP)-
咖啡酸类似物作为潜在的L
SD1
抑制剂,通过
TRAP染色法评估其对破骨细胞生成的抑制作用,并尝试探索初步的
SAR。其中,
TCP-MP-CA()显示出破骨细胞骨丢失,与L
SD1
抑制剂GSK-L
SD1相比,显示出效果显着改善。此外,我们还阐明了其前体通过FAD直接与L
SD1/CoREST复合物结合,抑制L
SD1去甲基化活性并影响其下游IκB/NF-κB信号通路,从而调节破骨细胞骨丢失的机制。这些发现表明或作为治疗破骨细胞性骨质流失的潜在新候选者,以及进一步开发
TCP-(MP)-
咖啡酸类似物用于骨质疏松症诊所治疗用途的概念。